Trial · NCT00709956

Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709956, Phase 3, Completed, Actelion; results first posted 2012-10-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Iloprost Power 15 in Pulmonary Arterial Hypertension. Trials, record NCT00709956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00709956

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT number: NCT00709956
Status: Completed
Phases: Phase 3
Enrollment: 64 participants, actual
Lead sponsor: Actelion
Conditions: Pulmonary Arterial Hypertension
Interventions: iloprost (5 µg), placebo
First posted: 2008-07-03
Last updated: 2025-02-04
Results first posted: 2012-10-26

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	6-minute-walk Distance (6MWD)	Study day 2 or study day 3	The 6-minute walk test was performed 20-40 minutes after treatment. This was a non-encouraged test (the person conducting the test did not encourage the patient to walk farther or faster) that measured the distance covered over a 6-minute walk. It was conducted by a trained member of the site staff who was listed on the site's delegation of authority sheet. For patients who had never performed a 6-minute walk test previously, a training test was requested before the qualifying tests for randomization.
Secondary	Borg Dyspnea Score	Study day 2 or study day 3	The Borg scale is a category-ratio scale, commonly used to evaluate the effects of exercise on dyspnea. The original and modified scales have ratio properties ranging from 0 = nothing at all to 10 = very, very severe, with descriptors from 0 to 10. Descriptors have been modified by others so that 10 has been labeled "extremely severe," or "the worst possible dyspnea imaginable." Reliability and validity have been reported in a general population and in patients with PAH as well as other respiratory conditions.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	6-minute-walk Distance (6MWD)	Study day 2 or study day 3	The analysis was per protocol, 64 patients started double blind phase of study, 63 completed.	meters	LEAST_SQUARES_MEAN
SECONDARY	Borg Dyspnea Score	Study day 2 or study day 3	The analysis was per protocol, 64 patients started double blind phase of study, 63 completed.	scores on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
6-minute-walk Distance (6MWD)	6MWD After Placebo Treatment	330.0	95% Confidence Interval 22.84	meters
6-minute-walk Distance (6MWD)	6MWD After Iloprost (5 µg) Treatment	328.6	95% Confidence Interval 55.28	meters
Borg Dyspnea Score	Borg Dyspnea Score After Placebo Treatment	3.5	Standard Deviation 2.23	scores on a scale
Borg Dyspnea Score	Borg Dyspnea Score After Iloprost (5 µg) Treatment	3.4	Standard Deviation 2.25	scores on a scale

Source ClinicalTrials.gov

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Iloprost (5µg) / Placebo	33
Overall Study	STARTED	Placebo / Iloprost (5 µg)	37
Overall Study	Double-blind Crossover-period	Iloprost (5µg) / Placebo	31
Overall Study	Double-blind Crossover-period	Placebo / Iloprost (5 µg)	33
Overall Study	COMPLETED	Iloprost (5µg) / Placebo	30
Overall Study	COMPLETED	Placebo / Iloprost (5 µg)	33
Overall Study	NOT COMPLETED	Iloprost (5µg) / Placebo	3
Overall Study	NOT COMPLETED	Placebo / Iloprost (5 µg)	4

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Cough	Respiratory, thoracic and mediastinal disorders	Iloprost (5µg) / Placebo	4	31
other	Cough	Respiratory, thoracic and mediastinal disorders	Placebo / Iloprost (5 µg)	4	33
other	Diarrhoea	Gastrointestinal disorders	Iloprost (5µg) / Placebo	0	31
other	Diarrhoea	Gastrointestinal disorders	Placebo / Iloprost (5 µg)	2	33
other	Dizziness	Nervous system disorders	Iloprost (5µg) / Placebo	2	31
other	Dizziness	Nervous system disorders	Placebo / Iloprost (5 µg)	4	33
other	Dysphonia	Respiratory, thoracic and mediastinal disorders	Iloprost (5µg) / Placebo	2	31
other	Dysphonia	Respiratory, thoracic and mediastinal disorders	Placebo / Iloprost (5 µg)	0	33
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Iloprost (5µg) / Placebo	1	31
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Placebo / Iloprost (5 µg)	3	33

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Iloprost (5µg) / Placebo
Total, all-cause mortality	Placebo / Iloprost (5 µg)
Total, other adverse events	Iloprost (5µg) / Placebo	16	31
Total, other adverse events	Placebo / Iloprost (5 µg)	20	33
Total, serious adverse events	Iloprost (5µg) / Placebo	0	31
Total, serious adverse events	Placebo / Iloprost (5 µg)	1	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Iloprost (5µg) / Placebo vs Placebo / Iloprost (5 µg): serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00709956

GET https://conductscience.org/api/trials/v1/NCT00709956/events?page=2

API reference For AI assistants